Search

everythinglearnresearchcommunity

for

Search:↓

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Minoxidil effective for regrowth but causes dryness; finasteride stops hair loss but may affect hormones; dutasteride powerful but reduces libido; RU58841 thickens hair but expensive and risky; dermarolling improves blood flow and results; aminexil overrated and not effective. Dermarolling beneficial with both minoxidil and finasteride.

Switching from Arimidex to Raloxifene worsened hair loss despite using Dutasteride. The user added oral Minoxidil, dermastamping, and RU58841 to their regimen to address the issue.

The conversation discusses hair loss treatments, specifically the use of anti-androgens like RU58841 and Pyrilutamide, which are expensive in India. Alternatives like spironolactone and concerns about the effectiveness of finasteride and dutasteride are also mentioned.

Dutasteride is more effective than finasteride for hair loss as it blocks more of the enzyme causing hair loss. New treatments like stem cell therapies and alternatives to minoxidil are being explored, but major advancements are still years away.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

Alcohol-based minoxidil absorbs better but can cause irritation; non-alcohol-based is gentler. Topical dutasteride shows promise but needs more research; low-dose oral minoxidil (0.25 mg/day) is effective with fewer side effects. Ingredients like Procapil, Redensyl, caffeine, and Anagain in shampoos have limited evidence; ketoconazole shampoo can help when used 2-3 times a week with other treatments.

Pyrilutamide is considered to work for hair loss but less effectively than expected, similar to RU58841, and may cause side effects like chest tightness and sexual issues. It's unclear if it's suitable for diffuse thinners, and one user cannot use minoxidil or finasteride due to side effects and personal circumstances.

Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.

Finasteride, dutasteride, and minoxidil can help prevent or slow hair loss for many, though results vary. The dermatologist's claim that no medication works is incorrect, as these treatments are effective for some individuals.

The user experienced severe side effects from finasteride, including anxiety and libido issues, and is currently using topical minoxidil and microneedling. They are considering trying dutasteride but are concerned about potential side effects.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

User quit minoxidil and finasteride, starting stemoxydine, dermastamp, and dermapen for hair loss. Seeks advice on alternatives, avoiding androgen disruptors and vasodilators/vasoconstrictors.

L. reuteri, a probiotic, is being explored for its potential benefits in treating androgenic alopecia, possibly enhancing finasteride's effects and reducing inflammation. The user combines this with finasteride, oral minoxidil, and other supplements, noting some improvement in hair loss.

Latanoprost/bimatoprost's effectiveness in hair loss treatment is discussed, with its potential to convert vellus hairs to terminal hairs. It works differently from minoxidil and finasteride, and may be best for hairline application, but is not a replacement for them due to price and mechanism.

Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

The user plans to lower their oral minoxidil dose from 5 mg to 2.5 mg to reduce side effects like puffiness and hypertrichosis, while also using finasteride and accutane. They are considering caffeine serums for puffiness and discussing dietary changes or switching to topical minoxidil to address bloating.

A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.

PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.

A product with Minoxidil, finasteride, and RU58841 may help with hair thinning, but effectiveness varies, especially in aggressive cases. More potent treatments might be necessary for severe androgenetic alopecia (AGA).

Finasteride and dutasteride can affect sexual function, cognition, and mood. Alternatives like minoxidil, pyrilutamide, and alfatradiol have varied effectiveness and side effects.

Consider increasing dutasteride dosage to 2.5mg daily and continue using oral minoxidil. Check DHT levels, thyroid, vitamin D, and consider additional treatments like microneedling, RU58841, and improving diet and lifestyle.

Dutasteride at 0.5mg blocks 50% of scalp DHT, while higher doses like 1mg and 2.5mg block more, with 2.5mg blocking up to 80%. Some users report better results with lower doses, and there's confusion about the effectiveness of different dosages on scalp versus serum DHT.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.